Dr Reddy’s Is Ready For Rituximab Registrations
Indian Firm Is Planning Filings For Rituxan Biosimilar In US And Europe
Dr Reddy’s is preparing for rituximab filings in the US, Europe and other regions after successfully clearing clinical trials for its DRL RI proposed biosimilar rival to Rituxan.
You may also be interested in...
Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.
The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.
Nine years after the launch of its biosimilar rituximab in India, Dr Reddy's Laboratories (DRL) claims a tenfold increase in the number of patients treated with the monoclonal antibody. M V Ramana, DRL's executive vice president and head branded markets (India and emerging countries) tells Scrip about his plans for the product in Russia and elsewhere and the firm's thrust on delivering care beyond the pill.